Biography
Dr. Bharadwaj is fellowship-trained in blood and marrow transplantation, cellular therapy, hematology, and oncology. She is an instructor in the Stanford School of Medicine Department of Medicine, Division of Blood & Marrow Transplantation and Cellular Therapy.
Dr. Bharadwaj focuses her expertise on diagnosing and treating cancer in blood and bone marrow. For each patient, she develops a personalized, comprehensive, and compassionate care plan. In her diverse experience as a physician and scientist, she has served as an internal medicine doctor, hospitalist, hematologist, oncologist, and blood and marrow transplantation specialist. Dr. Bharadwaj has a degree in clinical research and is currently conducting clinical trials in transplant and cellular therapy.
She has participated in research studies of advances in therapy for chronic lymphocytic leukemia, melanoma, and breast cancer. She has co-authored articles published in Leukemia and Lymphoma and elsewhere. Topics include advances in cell transplantation. She also co-wrote the chapter on genome-driven personalized cancer therapy in the book Precision Medicine in Oncology.
Dr. Bharadwaj has made presentations at meetings of the American Society of Hematology, American Society of Clinical Oncology, and other associations.
Subjects include racial, demographic, and socioeconomic disparities in the treatment of patients with acute myeloid leukemia.
Dr. Bharadwaj is a member of the American Society for Transplantation and Cellular Therapy, American Society of Hematology, and American Society of Clinical Oncology.
Dr. Bharadwaj focuses her expertise on diagnosing and treating cancer in blood and bone marrow. For each patient, she develops a personalized, comprehensive, and compassionate care plan. In her diverse experience as a physician and scientist, she has served as an internal medicine doctor, hospitalist, hematologist, oncologist, and blood and marrow transplantation specialist. Dr. Bharadwaj has a degree in clinical research and is currently conducting clinical trials in transplant and cellular therapy.
She has participated in research studies of advances in therapy for chronic lymphocytic leukemia, melanoma, and breast cancer. She has co-authored articles published in Leukemia and Lymphoma and elsewhere. Topics include advances in cell transplantation. She also co-wrote the chapter on genome-driven personalized cancer therapy in the book Precision Medicine in Oncology.
Dr. Bharadwaj has made presentations at meetings of the American Society of Hematology, American Society of Clinical Oncology, and other associations.
Subjects include racial, demographic, and socioeconomic disparities in the treatment of patients with acute myeloid leukemia.
Dr. Bharadwaj is a member of the American Society for Transplantation and Cellular Therapy, American Society of Hematology, and American Society of Clinical Oncology.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Hematology (2021)
- Fellowship: Stanford University Bone Marrow Transplant Fellowship (2021) CA
- Fellowship: Cook County Health Hematology Oncology Fellowship (2020) IL
-
- Residency: John H Stroger Jr Hospital of Cook County Internal Medicine Residency (2013) IL
- Internship: University of Illinois College of Medicine at Peoria (2011) IL
- Medical Education: Kasturba Medical College Mangalore (2006) India
Honors & Awards
- ASTCT Clinical Research Training Course Scholar, ASTCT (2022)
- Organizational Excellence Award, South Zone Pharmacology Conference, Mangalore, India
-
Publications
-
Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation
Nathan, S., Bharadwaj, S., Luke, K., Kalas, L., Katz, D. A., Hussain, M. J., … Ustun, C. (2020). Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation. LEUKEMIA & LYMPHOMA, 61(8), 2008–2011. -
Gender and glaucoma: what we know and what we need to know
Vajaranant, T. S., Nayak, S., Wilensky, J. T., & Joslin, C. E. (2010). Gender and glaucoma: what we know and what we need to know. CURRENT OPINION IN OPHTHALMOLOGY, 21(2), 91–99. -
Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes.
Abraham, I. E., Rauscher, G. H., Patel, A. A., Pearse, W., Rajakumar, P., Burkart, M., … Khan, I. (1800). Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes. Blood. -
-
Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance
Younes, S., Libert, D., Zhao, S., Johnsrud, A., Bharadwaj, S., Majzner, R., … Natkunam, Y. (2022). Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance. MODERN PATHOLOGY. SPRINGERNATURE. -
Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance
Younes, S., Libert, D., Zhao, S., Johnsrud, A., Bharadwaj, S., Majzner, R., … Natkunam, Y. (2022). Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance. LABORATORY INVESTIGATION. SPRINGERNATURE. -
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., … Muffly, L. (2022). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy. -
Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy
Nie, E., Ahmadian, S., Bharadwaj, S., Acosta-Alvarez, L., Threlkeld, Z., Frank, M., … Vogel, H. (2022). Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. OXFORD UNIV PRESS INC. -
Geriatrics assessment in older adults referred for hematopoietic cell transplantation.
Sossenheimer, P. H., Bharadwaj, S., Johnston, L., & Periyakoil, V. S. (2022). Geriatrics assessment in older adults referred for hematopoietic cell transplantation. Journal of the American Geriatrics Society. -
Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
Nie, E. H., Ahmadian, S. S., Bharadwaj, S. N., Acosta-Alvarez, L., Threlkeld, Z. D., Frank, M. J., … Vogel, H. (2023). Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma. Journal of Neuropathology and Experimental Neurology. -
Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., … Agrawal, V. (2022). Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era. BLOOD. AMER SOC HEMATOLOGY. -
Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
Chin, M., Shizuru, J. A., Muffly, L., Shiraz, P., Johnston, L. J., Lowsky, R., … Arai, S. (2022). Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease. BLOOD. AMER SOC HEMATOLOGY. -
Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma
Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., … Dahiya, S. (2022). Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentille, C., Mina, A., Arai, S., … Frank, M. J. (2022). The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes. BLOOD. AMER SOC HEMATOLOGY. -
Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M. S., Good, Z., … Alizadeh, A. A. (2022). Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects. BLOOD. AMER SOC HEMATOLOGY. -
Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C. J., Atrash, S., … Hansen, D. K. (2022). Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience. BLOOD. AMER SOC HEMATOLOGY. -
Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance.
Younes, S., Zhao, S., Bharadwaj, S., Mosquera, A. P., Libert, D., Johnsrud, A., … Natkunam, Y. (2023). Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 100256. -
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C., Khouri, J., … Hansen, D. K. (2023). Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. -
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., … Janakiram, M. (2023). Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer Journal, 13(1), 158. -
Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.
Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., … Meyer, E. (2023). Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD. Blood Advances. -
TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
Libert, D., Zhao, S., Younes, S., Mosquera, A. P., Bharadwaj, S., Ferreira, C., & Natkunam, Y. (2023). TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy. The American Journal of Surgical Pathology. -
Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.
Nie, E. H., Su, Y.-J. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W.-K. K., … Frank, M. J. (2024). Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma. Blood Advances. -
Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.
Lee, D., Goyal, A., Wang, W. L., Ananth, S., Lau, E., Binkley, M. S., … Dahiya, S. (2024). Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient. EJHaem, 5(1), 153–156. -
CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., … Alizadeh, A. A. (2023). CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias. BLOOD. AMER SOC HEMATOLOGY. -
Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
Bharadwaj, S., Lau, E., Hashmi, A., Hamilton, M. P., Jensen, A., Goyal, A., … Dahiya, S. (2023). Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY. -
Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection
Ananth, S., Su, Y.-J., Hamilton, M. P., Agarwal, N., Weng, W.-K., Dahiya, S., … Frank, M. J. (2023). Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection. BLOOD. AMER SOC HEMATOLOGY. -
Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus
Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., … McClellan, S. (2023). Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus. BLOOD. AMER SOC HEMATOLOGY. -
Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
Bharadwaj, S., Lau, E., Goyal, A., Hamilton, M. P., Srinagesh, H., Jensen, A., … Dahiya, S. (2023). Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY. -
Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)
Goyal, A., Bharadwaj, S., Lee, D., Lau, E., Hamilton, M. P., Jensen, A., … Dahiya, S. (2023). Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY. -
CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-. Cytokine Signature
Srinagesh, H., Baird, J. H., Agarwal, N., Su, Y.-J., Kramer, A. M., Reschke, A., … Frank, M. J. (2023). CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-. Cytokine Signature. BLOOD. AMER SOC HEMATOLOGY. -
Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)
Dahiya, S., Spiegel, J. Y., Lee, D., Mohammed, T., Lutfi, F., Goyal, A., … Jain, M. D. (2023). Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY. -
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., … Muffly, L. (2024). CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. Leukemia. -
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., … Miklos, D. B. (2024). CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Advances. -
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., … Dahiya, S. (2024). Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. Journal for Immunotherapy of Cancer, 12(7). -
A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., … Muffly, L. (2024). A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. Blood. -
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., … Miklos, D. B. (2024). CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet (London, England). -
Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)
Winter, A. M., Bharadwaj, S., Herrera, A. F., Iragavarapu, C., Mirza, S., Palomba, M. L., … Pasquini, M. C. (2024). Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.
Chin, M. M., Tamaresis, J. S., Johnston, L. J., Lowsky, R., Meyer, E., Muffly, L., … Arai, S. (2024). Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice. Bone Marrow Transplantation. -
A 17-Year Experience of a Large Dedicated Fellowship in Blood and Marrow Transplantation and Cellular Therapy: A Blueprint for Modern Day Training Program.
Bharadwaj, S., Lowsky, R., Mikkilineni, L., Smith, M., & Weng, W.-K. K. (2024). A 17-Year Experience of a Large Dedicated Fellowship in Blood and Marrow Transplantation and Cellular Therapy: A Blueprint for Modern Day Training Program. Journal of Cancer Education : the Official Journal of the American Association for Cancer Education. -
ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Miklos, D., Bharadwaj, S., Holmes, H., Oluwole, O., Jallouk, A., Neelapu, S., … Pinilla, J. (2024). ALPHA2: A Phase 1b Study Evaluating the CD19 Allogeneic CAR T Cell Product Cemacabtagene Ansegedleucel (Cema-Cel) in Patients With Relapsed/ Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Real-World Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients With Richter Transformation (RT) From the Center for International Blood and Marrow Transplant Research (CIBMTR)
Mirza, A.-S., Winter, A., Bharadwaj, S., Herrera, A. F., Iragavarapu, C., Palomba, M. L., … Pasquini, M. C. (2024). Real-World Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients With Richter Transformation (RT) From the Center for International Blood and Marrow Transplant Research (CIBMTR). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS
Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., … Meyer, E. (2024). PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS. BONE MARROW TRANSPLANTATION. SPRINGERNATURE. -
Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL.
Su, Y.-J. J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Srinagesh, H. K., Baird, J. H., … Frank, M. J. (2025). Effects of an initial anti-CD19 CAR T-cell therapy on subsequent anti-CD22 CAR T-cell manufacturing and clinical outcomes in patients with r/r LBCL. Cancer Discovery. -
Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.
Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., … Negrin, R. S. (2025). Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease. Blood. -
CCL8/CCL13-producing tumor-associated macrophages linked to poor outcomes after CAR T cell therapy for LBCL
Mo, K. C., Yeh, C. Y., Hamilton, M. P., Spiegel, J., Desai, M., Ehlinger, Z., … Good, Z. (2024). CCL8/CCL13-producing tumor-associated macrophages linked to poor outcomes after CAR T cell therapy for LBCL. Blood. San Diego. -
Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma
Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A. N. B., … Mikkilineni, L. (2024). Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma. BLOOD. ELSEVIER. -
Lisocabtagene Maraleucel for Richter's Transformation-A Case Series.
Smith, C. J., Goyal, A., Smith, B. R., Lee, D., Jensen, A., Alexander, J., … Bharadwaj, S. (2025). Lisocabtagene Maraleucel for Richter's Transformation-A Case Series. EJHaem, 6(2), e270011. -
Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy.
Ananth, S., Torres, N. E., Sahaf, B., Mikkilineni, L., Fernandez-Pol, S., Salmi, D., … Sidana, S. (2025). Fatal Recurrence of IEC-HS Following Autologous Stem Cell Boost in Patients Receiving BCMA CAR-T Cell Therapy. Blood Advances. -
Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A. M., Srinagesh, H., … Alizadeh, A. A. (2024). Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms. BLOOD. ELSEVIER. -
CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
Kramer, A. M., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., … Frank, M. J. (2024). CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up. BLOOD. ELSEVIER. -
Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL
Muffly, L., Ananth, S., Danley, L., Wagner, C., Kordek, D., Denoble, K., … Smith, M. (2024). Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL. BLOOD. ELSEVIER. -
CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
Kramer, A. M., Srinagesh, H., Su, Y.-J., Hamilton, M. P., Levine, K., Migliore, E., … Frank, M. J. (2024). CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma. BLOOD. ELSEVIER. -
Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged > 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Lee, D., Bharadwaj, S., Rana, M. S., Jensen, A., Wang, W., Ghalehsari, N., … Dahiya, S. (2024). Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged > 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL). BLOOD. ELSEVIER. -
Investigating Treatment Kinetics and Local Response during and after Bridging Radiotherapy Prior to CAR-T Cell Therapy for Lymphomas
Klebaner, D., Park, N., Marar, M., Frank, M. J., Hiniker, S., Hoppe, R. T., … Binkley, M. S. (2024). Investigating Treatment Kinetics and Local Response during and after Bridging Radiotherapy Prior to CAR-T Cell Therapy for Lymphomas. BLOOD. ELSEVIER. -
Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T)
Homsy, S., Seki, T., Nguyen, H. D., Shimura, A., Gorantla, N., Phuong, N. J., … Shinozaki, G. (2024). Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T). BLOOD. ELSEVIER. -
Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma
Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., … Sidana, S. (2024). Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma. BLOOD. ELSEVIER. -
The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024.
Uzun, D., Paul, J. M., Jensen, A., Tamaresis, J., Domingo, W., Arai, S., … Mikkilineni, L. (2025). The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024. Transplantation and Cellular Therapy. -
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort.
Elias, S., Brown, S., Egini, O., Walji, M., Homsy, S., Velayati, A., … Gyurkocza, B. (2025). Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort. Blood Cancer Journal, 15(1), 208. -
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.
Hamilton, M. P., Phillips, N., Noordenbos, T., Boegeholz, J., Sugio, T., Sworder, B. J., … Alizadeh, A. A. (2025). CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. Research Square. -
Immune Reconstitution, Vaccine Protection, and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
Moscvin, M., Goyal, A., Jensen, A., Epstein, D., Hovanky, V., Mikkilineni, L., … Sidana, S. (2025). Immune Reconstitution, Vaccine Protection, and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/Refractory Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma
Goyal, A., Bharadwaj, S., Lau, E., Jensen, A., Hamilton, M., Lee, C., … Dahiya, S. (2025). Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.
Klebaner, D., Park, N. J., Marar, M., Frank, M., Hiniker, S. M., Hoppe, R. T., … Binkley, M. S. (2025). Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas. Leukemia & Lymphoma, 1–8. -
Impact of Complete Response on Long-Term Survival in Patients With Relapsed or Refractory Large B-cell Lymphoma: A CIBMTR Prospective Study and SLR/Meta-Analysis.
Ghobadi, A., Anagnostou, T., Azzi, J., Hamadani, M., Logan, B., Ahmed, S., … Pasquini, M. C. (2026). Impact of Complete Response on Long-Term Survival in Patients With Relapsed or Refractory Large B-cell Lymphoma: A CIBMTR Prospective Study and SLR/Meta-Analysis. Transplantation and Cellular Therapy. -
Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., … Smith, M. (2025). Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL. BLOOD. ELSEVIER. -
Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT
Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., … Kennedy, V. (2025). Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT. BLOOD. ELSEVIER. -
Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study
Lee, D. (C., Rodrigues, K., Rana, M., Kozy, K., Salazar, S., Jensen, A., … Dahiya, S. (2025). Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study. BLOOD. ELSEVIER. -
Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post-CAR-T therapy
Rana, M., Ghalehsari, N., Jensen, A., Lee, D. (C., Park, N., Goyal, A., … Dahiya, S. (2025). Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post-CAR-T therapy. BLOOD. ELSEVIER. -
Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy
Ananth, S., Mallampet, J., Chang, B., Agarwal, N., Kong, K., Sahaf, B., … Frank, M. (2025). Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy. BLOOD. ELSEVIER. -
CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity
Srinagesh, H., Kramer, A. M., Hamilton, M., Su, Y.-J., Kozy, K., Jackson, L., … Frank, M. (2025). CD22-directed CAR-T cells induce complete remissions in high-risk follicular and Mantle Cell Lymphoma with limited neurotoxicity. BLOOD. ELSEVIER. -
Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation
Molina, A., Bubb, Q., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., … Kennedy, V. (2025). Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation. BLOOD. ELSEVIER. -
Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study
Villar-Prados, A., Kim, P., Sutherland, K., Negrin, R., Arai, S., Frank, M., … Meyer, E. (2025). Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study. BLOOD. ELSEVIER. -
Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM)
Rana, M., Jensen, A., Velayati, A., Hovanky, V., Muffly, L., Sahaf, B., … Sidana, S. (2025). Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in Relapsed/Refractory multiple myeloma (RRMM). BLOOD. ELSEVIER. -
From response to rupture: Evaluating GI perforation after CD19 CAR-T in LBCL
Velayati, A., Rana, M., Jensen, A., Lee, D. (C., Ghalehsari, N., Goyal, A., … Dahiya, S. (2025). From response to rupture: Evaluating GI perforation after CD19 CAR-T in LBCL. BLOOD. ELSEVIER. -
Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia
Huang, J., Voutsinas, J., Khaire, N., Pizzuti, V., Shune, L., Lei, M., … Shadman, M. (2025). Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia. BLOOD. ELSEVIER. -
Pre-treatment CDI9 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL
Spiegel, J., Oak, J., Rana, M., Jensen, A., Lee, D. (C., Nguyen-Mau, S.-M., … Dahiya, S. (2025). Pre-treatment CDI9 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL. BLOOD. ELSEVIER. -
Allogeneic hematopoietic cell transplantation for acute leukemia patients not in complete remission
Elias, S., Brown, S., Egini, O., Walji, M., Homsy, S., Velayati, A., … Gyurkocza, B. (2025). Allogeneic hematopoietic cell transplantation for acute leukemia patients not in complete remission. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
AI-Quantified Patient Frailty Predicts Clinical Response to CAR-T
Smith, C. J., Fettahoglu, A., Johnston, A., Smith, B. R., Mikkilinenni, L., Sidana, S., … Bharadwaj, S. (2026). AI-Quantified Patient Frailty Predicts Clinical Response to CAR-T. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC. -
Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy
Kennedy, V. E., Lauer, M., Shiraz, P., Arai, S., Johnston, L., Bharadwaj, S., … On, S. (2026). Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC. -
Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients
Rana, M. S., Kaveh, N., Jensen, A., Kennedy, V. E., Weng, W.-K., Smith, M., … Sidana, S. (2026). Impact of Social Determinants of Health on Access to CAR-T Therapy and Outcomes in Multiple Myeloma Patients. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC. -
Impact of Baseline and Dynamic IMWG Simplified Frailty Scores on Outcomes after CAR T-cell and Bispecific Antibody Therapy in Multiple Myeloma
Zhang, A. Q., Uzun, D., Yeung, S. B., Kondapally, Y. R., Austin, R., Jensen, A., … Mikkilineni, L. (2026). Impact of Baseline and Dynamic IMWG Simplified Frailty Scores on Outcomes after CAR T-cell and Bispecific Antibody Therapy in Multiple Myeloma. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC. -
The Relationship of Baseline and Longitudinal Frailty and Inflammatory Biomarkers with CAR-T Treatment Outcomes in Relapsed Refractory Myeloma
Yeung, S. B., Kondapally, Y. R., Uzun, D., Zhang, A. Q., Austin, R., Jensen, A., … Mikkilineni, L. (2026). The Relationship of Baseline and Longitudinal Frailty and Inflammatory Biomarkers with CAR-T Treatment Outcomes in Relapsed Refractory Myeloma. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC. -
Impact of IMWG Frailty and Nutritional Biomarkers on Outcomes in MM Pts Undergoing ASCT
Uzun, D., Zhang, A. Q., Austin, R., Yeung, S. B., Kondapally, Y. R., Jensen, A., … Mikkilineni, L. (2026). Impact of IMWG Frailty and Nutritional Biomarkers on Outcomes in MM Pts Undergoing ASCT. TRANSPLANTATION AND CELLULAR THERAPY. ELSEVIER SCIENCE INC. -
Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS.
Wang, W. L., Lee, D., Cheung, E., Jensen, A., Rana, M. S., Goyal, A., … Dahiya, S. (2026). Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS. Blood Advances.
-
Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive
900 Blake Wilbur Dr, Fl 2
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereHematology Program Palo Alto, CA
Palo Alto, CA
Hematology Program
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Review Summary
Dr. Sushma Bharadwaj is seen as professional, kind, and compassionate. She is valued for her thoroughness in explanations, ensuring clarity and understanding. Patients appreciate that she takes the time to listen and address concerns, fostering a comfortable environment.
The summary was created by AI, based on recent patient reviews. Learn more
Was this result useful to you?
Patient Reviews
(58 reviews)
Dr. Bharadwaj addressed my questions with confidence and caring. She could speak in depth and detail about my medical history despite not seeing me on a regular basis.
Dr. B. is an extremely skilled transplant doctor, with a big heart. She really cares about my loved ones and me, and she is very honest with me about my future and what is best for me. Thanks for everything!
Excelente experiencia
Already provided this
Dr. B was very professional, caring and made me feel safe. She answered all my questions and made sure that I understood the progression of this treatment. She also let me know that I can always ask more questions at any time.
excellent job!
Professional doctors
She is outstanding.
Very personable and engaged
Dr B was fantastic as usual and this was a video conference
She explains things in a very, very user friendly way, and with such compassion and kindness. And she never makes me feel hurried. She gives us confidence in the whole journey, which is good for healing! and she really knows her stuff!
She speaks to me in ways i can clearly understand.
The Oncology Staff is great.
She is very good at explaining things…very clear. She is very personable which is very valuable to me during this time. Thank you.
We had a courteous and professional video visit.
We are grateful for her work at Stanford.
I feel very comfortable and safe with the care of Dr Sushma Bharadwaj
Doctor B is a great doctor!!
Doctor Sushma Bharadwaj., is amazing
Dr. Sushma Bharadwaj is very professional and polite. And is very thorough.
Great doctor thank you!
I’m impressed by the attention I received from Dr. Bharadwaj, including the initiative she’s taking to explore possible treatments, the thoroughness of her explanations, her patience answering questions and her empathy.
She’s always pepaired and knows my case well. Importantly, she takes the time to listen and give you the time needed to completely answer. Any questions or concerns. Very caring, Compassionate And skilled doctor. Highly recommended.
Love her
Professional, compassionate, bright and cheerful!
I really like her, very kind and professional and very good at explaining things.
Doctor Sushma, is amazing and professional.
Dr. Sushma Bharadwaj is a caring doctor. She listens to my comments and concerns and addresses all concerns. I feel very comfortable speaking with her. She is Kind, Polite, Professional and Compassionate. Thank you Dr. Sushma Bharadwaj.
Dr. Bharadwaj is really concerned about my wellness and recovery â ¤ï¸ â€ ðŸ©¹ Her concern is highly appreciated!
Dr Bharadwaj is a very kind and compassionate person and is very patient explaining medical procedures. I feel very grateful that she is my doctor,
Hugh Mallaney
She a great Dr she explains things so I understand stand and I never feel rushed.
She is amazing and very knowledgeable
She very easy to talk to and very through I enjoy talking to her
She’s a very nice person
She always takes the time necessary for a complete consultation. This is very much appreciate it.
Very nice and informative and to the point and listen to my input and suggestion and very clear on her diagnosis and her thoughts.
She was on time with her video visits and had all the information from my tests available for me . She was knowledgeable and extremely helpful about my choices for treatment. She is a credit to her profession and a caring Doctor .
Wonderful Doctor and easy to understand and work with.😀
I am thrilled that we will be able to consider a move forward with the transplant. It made my month.
Thanks
Dr B is fantastic, very thorough and dedicated
She is a great doctor I’m so lucky to have her as my doctor
She's been great! Thorough, patient, supportive and informative. She made an extremely tense and scary process one I thought I could do, after her patience and encouragement. She's a keeper!
All the medical staff are very professional and helpful. Facilities are clean and modern.
Makes you feel comfortable asking questions, doesn’t rush you
She’s a great doctor I’m very lucky to have her taking care or me.
Dr. Bharadwaj is very compassionate, caring and treats patients so well! Anu is aso very professional and caring. The best team ever!!!
Truly an awesome Doctor I’m very happy I was assigned to her
Thank you and Anu for your help
I am appreciative and grateful to Dr Bharadwaj and her team for managing me through this treatment process skillfully and successfully.
Loved Dr bhardwaj, anu, and the Social Worker. My dad has had such a rough ride since he got his lymphoma. Everyone in stanford gave such a positive vibe. Invluding the two lab assistantsthat took my dads blood. I'm so happy with how the dr. Explained everything to him and asked me to tell him too. When we left i could see my dad feeling happier since he knew more of whatwas going on with him and how to proceed.
Very informative. Thk u
I think Dr Bharadwaj is a very good and thorough Doctors
Dr Bharadwaj has been a very good listener and has consistently explained everything regarding my care in layman’s language so that there hasn’t been any misunderstandings. She has always been professional and compassionate and caring.
Dr Sushma Bharadwaj is very easy to talk to. She explains completely of whatever issue the patient has. She is caring, thoughtful, engaged. I am grateful and thankful that she's my bone marrow transplant doctor, made the process less rough. I'd also like to thank her nurse coordinator, Anu Stephen. Anu also has the same above qualities.
Hey Dr. B,
Just wanted to thank you for today’s call. I’m extremely happy to hear that my test results were good! It’s nice to know someone is looking out for me.
Look forward to our face to face in January.
Happy Holidays!!
Staff is always very professional and thorough. I appreciate each one of them.
Very kind and knowledgeable
Comments for the doctor:
Thank you doctor for going over everything with me. I appreciate all that you and your team are doing for me and everyone else in need. I’m truly thankful.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records